Conference reports

Option B+ Malawi

24th Conference on Retroviruses and Opportunistic Infections (CROI 2017), 13-16 February 2017, Seattle

Impressive HIV pipeline at CROI 2017

Paediatric HIV: CROI 2017

23rd Annual Conference of BHIVA, 4-7 April 2017, Liverpool

Drop in HIV incidence in gay men: frequent testing, early ART and PrEP

Prompt/early ART: Dean Street pilot project reports 75% uptake

Potential for phylogenetic analysis to show direction of HIV transmission

Community presentations: dental care, HIV awareness and access to formula milk

Initiatives for earlier HIV diagnosis: opt-out ER and home testing

No new HIV cases in 398 people using PrEP at Dean Street clinic

Other selections and webcasts

24th Conference on Retroviruses and Opportunistic Infections (CROI 2017), 13-16 February 2017, Seattle

Dose reduction potential of nanoparticle ARV formulations confirmed in humans

VRC01 in HIV-exposed newborns: first results support monthly injections for those at risk through breastfeeding

Raltegravir pharmacokinetic targets met in high-risk HIV-exposed infants

Tenofovir alafenamide exposure is modestly higher in children than adults

New HIV diagnoses in children in UK and Ireland continue to decline

World Health Organisation paediatric dosing tool

Pre-ART drug resistance in rural South Africa but limited clinical impact with good adherence

Immune-based therapy canakinumab reduces inflammatory markers in HIV positive people on ART

Significant interaction between once-weekly isoniazid/rifapentine and daily dolutegravir: study stopped due to toxicity

Increased risk of IRIS with integrase inhibitors reported in two studies

Breakthrough for treating XDR-TB and ameliorating TB-IRIS

PrEP in pregnancy does not increase poor birth outcomes

HIV cure research and basic science: capsules from CROI 2017

24th Conference on Retroviruses and Opportunistic Infections (CROI 2017), 13-16 February 2017, Seattle

Pharmacokinetics and full phase 2 results for bictegravir, a new integrase inhibitor

New NNRTI doravirine is non-inferior to darunavir/r in phase 3 treatment naive study

NRTI GS-9131 resurfaces at CROI 2017: in vitro sensitivity to nuke-resistant HIV

Dolutegravir exposure increases when fixed dose combination tablets are crushed

Pharmacokinetics, safety and efficacy of dolutegravir in very young children

Efavirenz, tenofovir and emtricitabine associated with fewest adverse birth outcomes in Botswana

Adverse pregnancy outcomes and risk factors in the PROMISE trial

Women on lopinavir/ritonavir-based regimens at conception at higher risk of preterm delivery in UK study

No increase in adverse birth outcomes with maternal TDF/FTC in US study

Dolutegravir monotherapy studies halted due to integrase resistance: dual therapy studies continue

No evidence of accelerated brain ageing in HIV positive people on effective ART

Acute infection with wild-type HIV on PrEP with good drug levels

Fit for purpose: antiretroviral treatment optimisation (Feb 2017)

Seattle-lite: pre-conference workshops – watch online

International Congress of Drug Therapy in HIV infection (Glasgow 2016), 23-26 October 2016

1000-fold mark-up for drug prices in high-income countries blocks access to HIV, HCV and cancer drugs

Once-daily raltegravir formulation matches twice-daily results in age, gender, race and baseline viral load/CD4 subgroup analyses

Attachment inhibitor GSK-934/BMS-068: 96-week subgroup analysis in treatment-experienced patients

Once-weekly albuvirtide infusion: early results of T-20-like compound

Simplifying HIV treatment: dual therapy works but monotherapy with either boosted-PIs or dolutegravir does not

Dolutegravir-based ART in combination with rifampicin-based TB treatment is safe in a small cohort of co-infected patients

Further reports of CNS-related side effects with dolutegravir

Generic PrEP bought online for UK use is validated by drug testing service

Immunology and HIV persistence – implications for a cure

Selected webcasts from Glasgow 2016

2nd HIV Research for Prevention Conference (HIVR4P) 2016, 17-20 October 2016, Chicago

A burgeoning PrEP pipeline: dozens of new drugs, formulations and delivery options

Second case of drug resistant HIV infection in person adherent on PrEP

TDF/FTC can be used as PrEP by breastfeeding mothers without risk to the baby

Potential for EFdA as PrEP to prevent HIV transmission in women and their infants

Antibody therapy leads to sustained post-treatment SIV control in macaques

18th International Workshop on Comorbidities, 12-13 September, New York, USA

Fanconi-like lab abnormalities reported with daily PrEP: shows importance of routine kidney monitoring

Bone loss with PrEP in MSM aged 18-24

Neurological side effects with integrase inhibitors cause low rates of discontinuation in clinical practice

Atripla three days a week for two years: pilot switch study reports undetectable viral load with better bone, kidneys and sleep

Raltegravir increases waist circumference more than boosted PIs: greater with use of later ART

Exercise associated with significantly reduced risk of serious health problems and higher CD4 counts in large multicentre US study

Post navigation